Format

Send to

Choose Destination
Expert Opin Pharmacother. 2010 Jun;11(9):1459-66. doi: 10.1517/14656561003792538.

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.

Author information

1
University Hospital South Manchester, Wythenshawe Hospital, Department of Diabetes & Endocrinology, Southmoor Road, Manchester M23 9LT, UK. naveed.younis@uhsm.nhs.uk

Abstract

OBJECTIVE:

To evaluate the benefits of aspirin in people with diabetes mellitus for the primary prevention of cardiovascular disease.

RESEARCH DESIGN/METHODS:

We searched MEDLINE and Cochrane database for randomized, controlled trials of aspirin in people with diabetes and no cardiovascular disease. Relative risks were determined using random-effects meta-analysis.

MAIN OUTCOME MEASURES:

Risk reduction of aspirin compared with control groups for major cardiovascular events.

RESULTS:

Six trials consisting of 7374 patients with diabetes showed no benefits of aspirin compared with non-aspirin users with regard to overall mortality, risk reduction (relative risk (RR) = 0.96, 95% CI 0.78 - 1.18, p = 0.71), major cardiovascular events (RR = 0.90, 95% CI 0.78 - 1.05, p = 0.17) and myocardial infarction (RR = 0.95, 95% CI 0.76 - 1.18, p = 0.63). Risk of major bleeding in the aspirin compared with the non-aspirin group was not significant (RR = 2.49, 95% CI 0.70 - 8.84, p = 0.16).

CONCLUSIONS:

Aspirin therapy did not reduce the risk of cardiovascular events. Existing trials were limited by small patient numbers and low cardiovascular event rates. The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes.

PMID:
20429671
DOI:
10.1517/14656561003792538
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Health
Loading ...
Support Center